You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202161 - 202170 of 207728 results
  1. A new device to improve screening of corneal transplant tissue

    SBC: Sarver & Associates Inc            Topic: NEI

    Marous, James R. An Eye Bank Endothelial Cell Counter Abstract Procurement of donor corneal tissue for transplant use is an important social service undertaken by largely underfunded eye banks. Tissue is not only harvested, but must be screened for a myriad of issues that may make the tissue unsuitable for transplant or pose a health risk to the tissue recipient. Donor tissue may be rejected for ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Next-generation PERG devices and methods

    SBC: JORVEC CORP.            Topic: NEI

    DESCRIPTION (provided by applicant): Glaucoma is one of a number of optic nerve diseases which lead to retinal ganglion cells (RGC) degeneration, ultimately manifesting in a functional loss of vision if left untreated. There exist a number of therapeuticapproaches to treat these conditions, but there are currently no clinical methods to detect the onset of RGC dysfunction. The Pattern Electroret ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Novel cell-based Restorative Approach in Treatment of Diabetes-related Retinopath

    SBC: TARGAZYME, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): Retinal vascular diseases remain a common cause of vision loss and blindness with diabetes as the most common condition leading to retinopathy in adults in Western society. In particular, with type 1 diabetes the majority of patients will develo diabetic retinopathy (DR) with about 20-30% becoming legally blind while in type 2 diabetes more than 60% of patients ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Fully Automatic ROP Screening System: NeoScan

    SBC: VisionQuest Biomedical Inc            Topic: NEI

    DESCRIPTION (provided by applicant): This Phase I project is motivated by current issues associated with screening for retinopathy of prematurity (ROP). ROP is the leading cause of blindness in infants. In recent years the number of infants at risk for ROPhas been increasing. In the United States, the rate of prematurity has risen from 9.4% of all births in 1981 to 12% in 2010, for a total of over ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Multi-modal AO-LSO Phase Gradient Imaging of the Inner Retina

    SBC: PHYSICAL SCIENCES INC.            Topic: NEI

    Project Summary/Abstract Powerful new Adapative Optics imaging technoIogies which sense ocular aberrations with a wave- front sensor and corrects them with a deformable mirror wave-front compensator, like Adaptive Optics Scanning Laser Ophthalmoscopy (AOSLO) and AO-OCT, provide detailed anatomical, physiological and functional information at the cellular level in the human eye. Physical Sciences ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Head-Steerable Device for Basic Vision Function

    SBC: VISIBILITY METRICS LLC            Topic: NEI

    # %and'()*++, -./01' ,and'( Total or near total blindness results in severe disability in spatial orientation and greatly restricts mobility. The National Eye Institute has identified as a priority the development of new technology for improving access ofblind persons to navigation resources. This application seeks support for the development of a lightweight, wearable vision aid th ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Sustained-Release of a Novel Neuroprotective Agent for Improved Glaucoma Therapy

    SBC: Graybug Vision, Inc.            Topic: NEI

    DESCRIPTION (provided by applicant): Glaucoma is a major cause of blindness, affecting over 70 million people worldwide. It is a neurodegenerative optic neuropathy in which vision loss results from the loss of retinal ganglion cells (RGC). Current therapies are all directed at lowering intraocular pressure (IOP), however, despite IOP lowering, RGC loss still continues in many patients. To improve ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Intraocular Aerosol Treatment for Inhibition of Proliferative Vitreoretinopathy

    SBC: MSP CORPORATION            Topic: NEI

    Project Summary Proliferative vitreoretinopathy (PVR) is a major complication of retinal detachments and is responsible for most of the failures in retinal reattachment surgeries. About 10% of retinal detachment patients suffer from PVR. These patients often have poor visual outcome despite multiple surgeries. Our previous work on inhibition of PVR has focused on pharmacological intervention concu ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Choroidal Blood Flow Imaging with Spectral Domain OCT

    SBC: BIOPTIGEN, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): Ophthalmic vascular diseases impact millions of Americans. Age-related macular degeneration and diabetic retinopathy are the two major diseases with a well- known vascular factor. The role of the vascular system in glaucoma and retinopathy of prematurity is more insidious. The vascular theory of glaucoma suggests that the blood supply to the eye is a contributo ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Sustained Release of a Novel IOP Lowering Agent for the Treatment of Glaucoma

    SBC: Graybug Vision, Inc.            Topic: NEI

    DESCRIPTION (provided by applicant): Glaucoma is a major cause of blindness, affecting over 70 million people worldwide. The development of glaucoma is most often associated with elevated intraocular pressure (IOP) which is induced by the dysfunction of the trabecular meshwork (TM) leading to inhibition of aqueous humor outflow. In most patients, constant elevated IOP results in the loss of retina ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government